Trimetrexate: A Critical Appraisal of the Phase II Clinical Trial Experience: Evidence of Drug Discovery-Clinical Development Disjunction
- 1 January 1994
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 12 (6) , 657-661
- https://doi.org/10.3109/07357909409023051
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Phase II Trial for the Evaluation of Trimetrexate in Patients with Inoperable Squamous Carcinoma of the EsophagusAmerican Journal of Clinical Oncology, 1992
- Trimetrexate in advanced renal cell carcinomaInvestigational New Drugs, 1992
- Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreasInvestigational New Drugs, 1990
- Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group StudyInvestigational New Drugs, 1990
- Treatment of metastatic malignant melanoma with trimetrexate: A phase II studyMedical and Pediatric Oncology, 1990
- Phase II trial of trimetrexate in patients with advanced renal cell carcinomaEuropean Journal of Cancer and Clinical Oncology, 1989
- Phase II Trial of Trimetrexate in Patients with Stage III and IV Non-Small-Cell Lung CancerAmerican Journal of Clinical Oncology, 1989
- Trimetrexate in advanced carcinoma of the esophagusInvestigational New Drugs, 1988
- Biochemical pharmacology of the lipophilic antifolate, trimetrexateAdvances in Enzyme Regulation, 1984
- Inhibition of Dihydrofolate Reductase and Cell Growth by Antifolates in a Methotrexate-Resistant Cell LineOncology, 1984